GLP-1 users report nail detachment at 39% in survey

GLP-1 users reported nail detachment in 39% of cases versus 9% of nonusers in research presented in October at the EADV Congress 2026 in Vienna, Healthline reported Oct. 7.

Evidence grade: Early (small, animal, cell or preprint). The finding comes from self-reported, cross-sectional conference abstracts, not a randomized trial, and compares 575 GLP-1 users with 1,329 nonusers with type 2 diabetes, obesity or both.

The nail study adds a dermatology safety signal to questions around GLP-1 medicines, including semaglutide products Ozempic and Wegovy and tirzepatide products Mounjaro and Zepbound. The abstract did not specify which GLP-1 drugs participants used.

Participants taking GLP-1 drugs reported nail discoloration at 46%, compared with 17% among nonusers, according to the abstract described by Healthline. Ridges or grooves and fragile nails were also more common among users, the report said.

Charles Taïeb, a study author, told Healthline that the association with nail detachment weakened sharply when researchers counted only nail changes that began after treatment. “This is why we insist that a substantial part of the nail excess reflects the patients’ overall health rather than the drug itself, while a modest drug-specific effect remains plausible,” Taïeb said.

The study population was drawn from France, the United States, Brazil and Mexico, Healthline reported. GLP-1 users had an average treatment duration of 18.5 months, and the researchers tracked weight loss over three months.

The results apply most directly to people like those surveyed: adults taking GLP-1 drugs and comparison participants with type 2 diabetes, obesity or both. They do not establish what would happen in people without those conditions or in users of a specific GLP-1 product.

The researchers also examined weight loss as a possible explanation. Over three months, 76% of GLP-1 users reported losing weight, compared with 47% of nonusers; Healthline said the nail differences persisted when the analysis was limited to people who had lost weight.

The study cannot establish that GLP-1 drugs were responsible for the nail changes. The researchers said about half of users had nail problems before starting treatment, and adjustments for self-reported skin conditions and nutritional deficiencies weakened some associations.

Nail detachment, or onycholysis, means the nail lifts from the nail bed; Healthline cited the American Academy of Dermatology for that definition. Taïeb said the questionnaire used the term “nail detachment” because participants, rather than clinicians, reported their own symptoms.

A companion abstract using the same participant group found hair and scalp symptoms were more common among GLP-1 users, Healthline reported. Unusual hair loss was reported by 50% of users versus 34% of nonusers, loss of hair volume or density by 42% versus 19%, and hair loss beginning after treatment by 26% versus 12%.

U.S. labels for Wegovy and Zepbound list hair loss as a side effect reported in clinical trials, Healthline said. Labels for Ozempic, in injectable and pill form, and Mounjaro list hair loss based on post-marketing reports, which do not establish frequency or responsibility.

Mir B. Ali, a bariatric surgeon who was not involved in the research, told Healthline that nail detachment has not been a common complaint in his practice: “I haven’t had anybody complain of that. It’s not something we really see,” he said.

Healthline reported that the nail findings have been submitted to peer-reviewed dermatology journals and remain under review. Funding and conflict disclosures were not described in the supplied Healthline report.

Source: Healthline News article, Oct. 7, 2026; EADV Congress 2026 press release and abstracts described by Healthline.

Atlas360 reports health research and does not provide medical advice.